AgomAb Therapeutics

Public

Ghent, FlandersBiotechhttps://agomab.com/

Last Round

IPO Announced

Feb 9, 2026

Est. Valuation

$779.8M

Total Funding Raised

$727M

Company Overview

AgomAb Therapeutics is a biopharmaceutical company that develops disease-modifying therapies for fibro-inflammatory diseases by targeting established pathways and utilizing organ-restricted approaches.

Sector

Biotech

Verticals

Life Sciences

AI Layer

Non-AI

Keywords

biotechnologybiotechdrug discoveryclinical-stagefibrotic diseasemonoclonal antibodysmall moleculeregenerative medicineclinical trialsgrowth factor signalingbiopharmatherapeutic candidatepipeline stock

AgomAb Therapeutics Comps

Public and private peers based on sector, stage, and business model.

AgomAb Therapeutics comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

AgomAb Therapeutics Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
IPO Announced	Feb 9, 2026
Series D	Oct 24, 2024
IPO Announced	Feb 5, 2024
Series C	Oct 11, 2023
Series B Extension	Jul 13, 2022
Series B	Mar 10, 2021

View all Funding Rounds

Key People

Founding team and executive leadership

Tim Knotnerus

CEO, CEO

Executive Team

AgomAb Therapeutics Investors

Notable investors and investment history

AgomAb Therapeutics investors
Investor	Rounds
Redmile Group	Series B
Asabys Partners	Series B Extension, Series D
Van Lanschot Kempen	IPO
Boehringer Ingelheim	Series B, Series A
Kohlberg Kravis Roberts	Series C
EQT Life Sciences	Series C
Morgan Stanley & Co., LLC	IPO

View all Investors

AgomAb Therapeutics Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

AgomAb Therapeutics Filings

SEC and related filings with document metadata.

Firmographic Details

HeadquartersGhent, Flanders

Employee Range72

Year Founded2017

Last FundingFeb 9, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.